Literature DB >> 29379199

Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.

Rhamy Zeid1, Matthew A Lawlor1, Evon Poon2,3, Jaime M Reyes1, Mariateresa Fulciniti1,4, Michael A Lopez1,4, Thomas G Scott1, Behnam Nabet1, Michael A Erb1, Georg E Winter1, Zoe Jacobson1, Donald R Polaski1, Kristen L Karlin5, Rachel A Hirsch5, Nikhil P Munshi1,4, Thomas F Westbrook5, Louis Chesler2,3, Charles Y Lin6,7, James E Bradner8,9,10.   

Abstract

Amplification of the locus encoding the oncogenic transcription factor MYCN is a defining feature of high-risk neuroblastoma. Here we present the first dynamic chromatin and transcriptional landscape of MYCN perturbation in neuroblastoma. At oncogenic levels, MYCN associates with E-box binding motifs in an affinity-dependent manner, binding to strong canonical E-boxes at promoters and invading abundant weaker non-canonical E-boxes clustered at enhancers. Loss of MYCN leads to a global reduction in transcription, which is most pronounced at MYCN target genes with the greatest enhancer occupancy. These highly occupied MYCN target genes show tissue-specific expression and are linked to poor patient survival. The activity of genes with MYCN-occupied enhancers is dependent on the tissue-specific transcription factor TWIST1, which co-occupies enhancers with MYCN and is required for MYCN-dependent proliferation. These data implicate tissue-specific enhancers in defining often highly tumor-specific 'MYC target gene signatures' and identify disruption of the MYCN enhancer regulatory axis as a promising therapeutic strategy in neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29379199      PMCID: PMC6310397          DOI: 10.1038/s41588-018-0044-9

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  63 in total

1.  MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.

Authors:  Jung-Hee Kang; Piotr G Rychahou; Titilope A Ishola; Jingbo Qiao; B Mark Evers; Dai H Chung
Journal:  Biochem Biophys Res Commun       Date:  2006-10-12       Impact factor: 3.575

2.  Targeted expression of MYCN causes neuroblastoma in transgenic mice.

Authors:  W A Weiss; K Aldape; G Mohapatra; B G Feuerstein; J M Bishop
Journal:  EMBO J       Date:  1997-06-02       Impact factor: 11.598

3.  Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.

Authors:  Daniel Muth; Seda Ghazaryan; Isabella Eckerle; Emily Beckett; Christina Pöhler; Julia Batzler; Claudia Beisel; Sina Gogolin; Matthias Fischer; Kai-Oliver Henrich; Volker Ehemann; Paul Gillespie; Manfred Schwab; Frank Westermann
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

4.  p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells.

Authors:  D A Tweddle; A J Malcolm; M Cole; A D Pearson; J Lunec
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

Review 5.  MYC oncogenes and human neoplastic disease.

Authors:  C E Nesbit; J M Tersak; E V Prochownik
Journal:  Oncogene       Date:  1999-05-13       Impact factor: 9.867

6.  Regulation of the neural crest cell fate by N-myc: promotion of ventral migration and neuronal differentiation.

Authors:  Y Wakamatsu; Y Watanabe; H Nakamura; H Kondoh
Journal:  Development       Date:  1997-05       Impact factor: 6.868

7.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

Authors:  R C Seeger; G M Brodeur; H Sather; A Dalton; S E Siegel; K Y Wong; D Hammond
Journal:  N Engl J Med       Date:  1985-10-31       Impact factor: 91.245

8.  Cell cycle regulation targets of MYCN identified by gene expression microarrays.

Authors:  Emma Bell; John Lunec; Deborah A Tweddle
Journal:  Cell Cycle       Date:  2007-05-01       Impact factor: 4.534

Review 9.  Promising therapeutic targets in neuroblastoma.

Authors:  Katherine K Matthay; Rani E George; Alice L Yu
Journal:  Clin Cancer Res       Date:  2012-05-15       Impact factor: 12.531

10.  The landscape of somatic copy-number alteration across human cancers.

Authors:  Rameen Beroukhim; Craig H Mermel; Dale Porter; Guo Wei; Soumya Raychaudhuri; Jerry Donovan; Jordi Barretina; Jesse S Boehm; Jennifer Dobson; Mitsuyoshi Urashima; Kevin T Mc Henry; Reid M Pinchback; Azra H Ligon; Yoon-Jae Cho; Leila Haery; Heidi Greulich; Michael Reich; Wendy Winckler; Michael S Lawrence; Barbara A Weir; Kumiko E Tanaka; Derek Y Chiang; Adam J Bass; Alice Loo; Carter Hoffman; John Prensner; Ted Liefeld; Qing Gao; Derek Yecies; Sabina Signoretti; Elizabeth Maher; Frederic J Kaye; Hidefumi Sasaki; Joel E Tepper; Jonathan A Fletcher; Josep Tabernero; José Baselga; Ming-Sound Tsao; Francesca Demichelis; Mark A Rubin; Pasi A Janne; Mark J Daly; Carmelo Nucera; Ross L Levine; Benjamin L Ebert; Stacey Gabriel; Anil K Rustgi; Cristina R Antonescu; Marc Ladanyi; Anthony Letai; Levi A Garraway; Massimo Loda; David G Beer; Lawrence D True; Aikou Okamoto; Scott L Pomeroy; Samuel Singer; Todd R Golub; Eric S Lander; Gad Getz; William R Sellers; Matthew Meyerson
Journal:  Nature       Date:  2010-02-18       Impact factor: 49.962

View more
  67 in total

1.  Functional Enhancers Shape Extrachromosomal Oncogene Amplifications.

Authors:  Andrew R Morton; Nergiz Dogan-Artun; Zachary J Faber; Graham MacLeod; Cynthia F Bartels; Megan S Piazza; Kevin C Allan; Stephen C Mack; Xiuxing Wang; Ryan C Gimple; Qiulian Wu; Brian P Rubin; Shashirekha Shetty; Stephane Angers; Peter B Dirks; Richard C Sallari; Mathieu Lupien; Jeremy N Rich; Peter C Scacheri
Journal:  Cell       Date:  2019-11-21       Impact factor: 41.582

2.  Analysis of Myc Chromatin Binding by Calibrated ChIP-Seq Approach.

Authors:  Donald P Cameron; Vladislav Kuzin; Laura Baranello
Journal:  Methods Mol Biol       Date:  2021

3.  Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma.

Authors:  Hiroto Ohguchi; Paul M C Park; Tingjian Wang; Berkley E Gryder; Daisuke Ogiya; Keiji Kurata; Xiaofeng Zhang; Deyao Li; Chengkui Pei; Takeshi Masuda; Catrine Johansson; Virangika K Wimalasena; Yong Kim; Shinjiro Hino; Shingo Usuki; Yawara Kawano; Mehmet K Samur; Yu-Tzu Tai; Nikhil C Munshi; Masao Matsuoka; Sumio Ohtsuki; Mitsuyoshi Nakao; Takashi Minami; Shannon Lauberth; Javed Khan; Udo Oppermann; Adam D Durbin; Kenneth C Anderson; Teru Hideshima; Jun Qi
Journal:  Cancer Discov       Date:  2021-04-10       Impact factor: 39.397

4.  Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.

Authors:  Jonas Ecker; Venu Thatikonda; Gianluca Sigismondo; Florian Selt; Gintvile Valinciute; Ina Oehme; Carina Müller; Juliane L Buhl; Johannes Ridinger; Diren Usta; Nan Qin; Cornelis M van Tilburg; Christel Herold-Mende; Marc Remke; Felix Sahm; Frank Westermann; Marcel Kool; Robert J Wechsler-Reya; Lukas Chavez; Jeroen Krijgsveld; Natalie Jäger; Stefan M Pfister; Olaf Witt; Till Milde
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

5.  Targeting the Chromosomal Passenger Complex Subunit INCENP Induces Polyploidization, Apoptosis, and Senescence in Neuroblastoma.

Authors:  Ming Sun; Veronica Veschi; Sukriti Bagchi; Man Xu; Arnulfo Mendoza; Zhihui Liu; Carol J Thiele
Journal:  Cancer Res       Date:  2019-08-15       Impact factor: 12.701

6.  Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma.

Authors:  Krista M Dalton; Timothy L Lochmann; Konstantinos V Floros; Marissa L Calbert; Richard Kurupi; Giovanna T Stein; Joseph McClanaghan; Ellen Murchie; Regina K Egan; Patricia Greninger; Mikhail Dozmorov; Sivapriya Ramamoorthy; Madhavi Puchalapalli; Bin Hu; Lisa Shock; Jennifer Koblinski; John Glod; Sosipatros A Boikos; Cyril H Benes; Anthony C Faber
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-30       Impact factor: 11.205

7.  Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth.

Authors:  Ekta Agarwal; Brian J Altman; Jae Ho Seo; Jagadish C Ghosh; Andrew V Kossenkov; Hsin-Yao Tang; Shiv Ram Krishn; Lucia R Languino; Dmitry I Gabrilovich; David W Speicher; Chi V Dang; Dario C Altieri
Journal:  J Biol Chem       Date:  2019-05-16       Impact factor: 5.157

8.  An early Myc-dependent transcriptional program orchestrates cell growth during B-cell activation.

Authors:  Alessandra Tesi; Stefano de Pretis; Mattia Furlan; Marco Filipuzzi; Marco J Morelli; Adrian Andronache; Mirko Doni; Alessandro Verrecchia; Mattia Pelizzola; Bruno Amati; Arianna Sabò
Journal:  EMBO Rep       Date:  2019-07-23       Impact factor: 8.807

9.  Myc Regulation of a Mitochondrial Trafficking Network Mediates Tumor Cell Invasion and Metastasis.

Authors:  Ekta Agarwal; Brian J Altman; Jae Ho Seo; Irene Bertolini; Jagadish C Ghosh; Amanpreet Kaur; Andrew V Kossenkov; Lucia R Languino; Dmitry I Gabrilovich; David W Speicher; Chi V Dang; Dario C Altieri
Journal:  Mol Cell Biol       Date:  2019-06-27       Impact factor: 4.272

10.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.

Authors:  Adeline Berger; Nicholas J Brady; Rohan Bareja; Brian Robinson; Vincenza Conteduca; Michael A Augello; Loredana Puca; Adnan Ahmed; Etienne Dardenne; Xiaodong Lu; Inah Hwang; Alyssa M Bagadion; Andrea Sboner; Olivier Elemento; Jihye Paik; Jindan Yu; Christopher E Barbieri; Noah Dephoure; Himisha Beltran; David S Rickman
Journal:  J Clin Invest       Date:  2019-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.